Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth

Journal of Clinical Investigation

Volumn 125, Issue 6, 2015, Pages 2523-2531

  Willis, Jordan R ^a,b   Sapparapu, Gopal ^b   Murrell, Sasha ^c   Julien, Jean Philippe ^c   Singh, Vidisha ^b   King, Hannah G ^b   Xia, Yan ^b,d   Pickens, Jennifer A ^b   La Branche, Celia C ^e   Slaughter, James C ^b   Montefiori, David C ^e   Wilson, Ian A ^c   Meiler, Jens ^a,d   Crowe, James E ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c International AIDS Vaccine Initiative Neutralizing Antibody Center   (United States)

^d VANDERBILT UNIVERSITY   (United States)

^e DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; NEUTRALIZING ANTIBODY; PG9 ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; COMPLEMENTARITY DETERMINING REGION; GLYCOPROTEIN GP 160; GP160 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTIBODY COMBINING SITE; ANTIGEN BINDING; ARTICLE; BINDING AFFINITY; COMPLEMENTARITY DETERMINING REGION; COMPUTER PROGRAM; CONTROLLED STUDY; CRYSTAL STRUCTURE; DIFFERENTIAL SCANNING CALORIMETRY; HEAVY CHAIN COMPLEMENTARITY DETERMINING REGION 3; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PRIORITY JOURNAL; THERMODYNAMICS; VIRUS NEUTRALIZATION; VIRUS STRAIN; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; PROTEIN TERTIARY STRUCTURE;

COMPLEMENTARITY DETERMINING REGIONS; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP160; HIV-1; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; SOFTWARE;

EID: 84930389498     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI80693     Document Type: Article

References (47)

1. Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013;31: 705-742.
2. McLellan JS, et al. Structure of HIV-1 gp120 V1/ V2 domain with broadly neutralizing antibody PG9. Nature. 2011;480(7377): 336-343.
3. Walker LM, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365): 466-470.
4. Pejchal R, et al. Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1. Proc Natl Acad Sci USA. 2010;107(25): 11483-11488.
5. Pancera M, et al. Crystal structure of PG16 and chimeric dissection with somatically related PG9: Structure-function analysis of two quaternary- specific antibodies that effectively neutralize HIV-1. J Virol. 2010;84(16): 8098-8110.
6. Pancera M, et al. Structural basis for diverse N-glycan recognition by HIV-1-neutralizing V1-V2-directed antibody PG16. Nat Struct Mol Biol. 2013;20(7): 804-813.
7. Fleishman SJ, et al. Computational design of proteins targeting the conserved stem region of influenza hemagglutinin. Science. 2011;332(6031): 816-821.
8. Fleishman SJ, et al. RosettaScripts: A scripting language interface to the Rosetta macromolecular modeling suite. PLoS One. 2011;6(6): E20161.
9. Kuhlman B, Baker D. Native protein sequences are close to optimal for their structures. Proc Natl Acad Sci USA. 2000;97(19): 10383-10388.
10. Kaufmann KW, Lemmon GH, Deluca SL, Sheehan JH, Meiler J. Practically useful: What the Rosetta protein modeling suite can do for you. Biochemistry. 2010;49(14): 2987-2998.
11. Kabat EA. Sequences of Proteins of Immunological Interest. Bethesda, Maryland, USA: US Department of Health and Human Services, Public Health Service, National Institutes of Health; 1991.
12. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950): 285-289.
13. Li M, et al. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol. 2005;79(16): 10108-10125.
14. Li M, et al. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in Southern Africa. J Virol. 2006;80(23): 11776-11790.
15. Emsley P, Cowtan K. Coot: Model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr. 2004;60(pt 12 pt 1): 2126-2132.
16. Julien JP, et al. Asymmetric recognition of the HIV-1 trimer by broadly neutralizing antibody PG9. Proc Natl Acad Sci USA. 2013;110(11): 4351-4356.
17. Sanders RW, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol. 2002;76(17): 8875-8889.
18. Sanders RW, et al. A next-generation cleaved, soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies. PLoS Pathog. 2013;9(9): E1003618.
19. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol. 2009;485: 395-405.
20. Doores KJ, Doores KJ, Burton DR, Burton DR. Variable loop glycan dependency of the broad and potent HIV-1-neutralizing antibodies PG9 and PG16. J Virol. 2010;84(20): 10510-10521.
21. Garber E, Demarest SJ. A broad range of Fab stabilities within a host of therapeutic IgGs. Biochem Biophys Res Commun. 2007;355(3): 751-757.
22. Ionescu RM, Vlasak J, Price C, Kirchmeier M. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci. 2008;97(4): 1414-1426.
23. Makhatadze GI, Privalov PL. Energetics of protein structure. Adv Protein Chem. 1995;47: 307-425.
24. Privalov PL, Khechinashvili NN. A thermodynamic approach to the problem of stabilization of globular protein structure: A calorimetric study. J Mol Biol. 1974;86(3): 665-684.
25. Yurasov S. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201(5): 703-711.
26. Briney BS, Willis JR, Crowe JE. Human peripheral blood antibodies with long HCDR3s are established primarily at original recombination using a limited subset of germline genes. PLoS One. 2012;7(5): E36750.
27. Haynes BF, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science. 2005;308(5730): 1906-1908.
28. Ramilo O, et al. Motavizumab treatment of infants hospitalized with respiratory syncytial virus infection does not decrease viral load or severity of illness. Pediatr Infect Dis J. 2014;33(7): 703-709.
29. Klein F, et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell. 2013;153(1): 126-138.
30. Willis JR, Briney BS, Deluca SL, Crowe JE, Meiler J. Human germline antibody gene segments encode polyspecific antibodies. PLoS Comput Biol. 2013;9(4): E1003045.
31. Schmidt AG, et al. Preconfiguration of the antigen- binding site during affinity maturation of a broadly neutralizing influenza virus antibody. Proc Natl Acad Sci USA. 2013;110(1): 264-269.
32. Wong SE, Sellers BD, Jacobson MP. Effects of somatic mutations on CDR loop flexibility during affinity maturation. Proteins. 2011;79(3): 821-829.
33. Schultz PG, Yin J, Lerner RA. The chemistry of the antibody molecule. Angew Chem Int Ed Engl. 2002;41(23): 4427-4437.
34. Wedemayer GJ, Patten PA, Wang LH, Schultz PG, Stevens RC. Structural insights into the evolution of an antibody combining site. Science. 1997;276(5319): 1665-1669.
35. Sok D, et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc Natl Acad Sci USA. 2014;111(49): 17624-17629.
36. Correia BE, et al. Proof of principle for epitope-focused vaccine design. Nature. 2014;507(7491): 201-206.
37. Jardine J, et al. Rational HIV immunogen design to target specific germline B cell receptors. Science. 2013;340(6133): 711-716.
38. McLellan JS, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science. 2013;342(6158): 592-598.
39. Lemmon G, Kaufmann K, Meiler J. Prediction of HIV-1 protease/inhibitor affinity using RosettaLigand. Chem Biol Drug Des. 2012;79(6): 888-896.
40. Xu R, Ekiert DC, Krause JC, Hai R, Crowe JE Jr, Wilson IA. Structural basis of preexisting immunity to the 2009 H1N1 pandemic influenza virus. Science. 2010;328(5976): 357-360.
41. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Protoc Immunol. 2005;Chapter 12: Unit 12.11.
42. Sarzotti-Kelsoe M, et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;409: 131-146.
43. Kabsch W. Integration, scaling, space-group assignment and post-refinement. Acta Crystallogr D Biol Crystallogr. 2010;66(pt 2): 125-132.
44. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(pt 4): 658-674.
45. Adams PD, et al. PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr D Biol Crystallogr. 2010;66(pt 2): 213-221.
46. Pettersen EF, et al. UCSF Chimera - A visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13): 1605-1612.
47. Lefranc MP. IMGT-ONTOLOGY and IMGT databases, tools and Web resources for immunogenetics and immunoinformatics. Mol Immunol. 2004;40(10): 647-660.